New Millennium Group LLC Sells 28,749 Shares of AstraZeneca PLC (NASDAQ:AZN)

New Millennium Group LLC lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 95.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,426 shares of the company’s stock after selling 28,749 shares during the period. New Millennium Group LLC’s holdings in AstraZeneca were worth $111,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. increased its stake in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter valued at $28,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca during the 1st quarter worth $29,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after buying an additional 146 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.1 %

Shares of NASDAQ:AZN opened at $63.46 on Tuesday. The firm has a market cap of $196.76 billion, a P/E ratio of 30.33, a P/E/G ratio of 1.17 and a beta of 0.47. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The business has a fifty day simple moving average of $74.68 and a 200 day simple moving average of $78.15. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the firm earned $0.87 earnings per share. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on AZN shares. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.